{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:50:06Z","timestamp":1761569406021,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clgc.2022.11.020","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T13:41:13Z","timestamp":1669729273000},"page":"273-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-9119","authenticated-orcid":false,"given":"Carlos E.","family":"Stecca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-2292","authenticated-orcid":false,"given":"Di Maria","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Veitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9286-1972","authenticated-orcid":false,"given":"Sebastian J","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimira","family":"Alimohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"Canadian Cancer Statistics: A 2018 Special Report on cancer incidence by stage","key":"10.1016\/j.clgc.2022.11.020_bib0001"},{"issue":"1","key":"10.1016\/j.clgc.2022.11.020_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"168","author":"Huggins","year":"2002","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.clgc.2022.11.020_bib0003","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2022.11.020_bib0004","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2022.11.020_bib0005","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Given R,et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.clgc.2022.11.020_bib0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Chi KN, Chowdhury S,et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.clgc.2022.11.020_bib0007","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clgc.2022.11.020_bib0008","doi-asserted-by":"crossref","first-page":"E154","DOI":"10.5489\/cuaj.6595","article-title":"Blais N,et al. Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic","volume":"14","author":"Lalani","year":"2020","journal-title":"Can Urol Assoc J"},{"issue":"18","key":"10.1016\/j.clgc.2022.11.020_bib0009","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1002\/cam4.4184","article-title":"A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer","volume":"10","author":"Tsaur","year":"2021","journal-title":"Cancer Med"},{"issue":"28","key":"10.1016\/j.clgc.2022.11.020_bib0010","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2022.11.020_bib0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.20892\/j.issn.2095-3941.2020.0289","article-title":"COVID-19 in cancer patients: risk, clinical features, and management","volume":"17","author":"Liu","year":"2020","journal-title":"Cancer Biol Med"},{"issue":"6","key":"10.1016\/j.clgc.2022.11.020_bib0012","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.clgc.2022.06.017","article-title":"Treatment intensification patterns and utilization in patients with metastatic castration-sensitive prostate cancer","volume":"20","author":"Heath","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2022.11.020_bib0013","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","article-title":"Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States","volume":"206","author":"Ryan","year":"2021","journal-title":"J Urol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2022.11.020_bib0014","article-title":"Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US)","volume":"38","author":"Ke","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2022.11.020_bib0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jnci\/djaa159","article-title":"Prevalence and outcome of COVID-19 infection in cancer patients: a national veterans affairs study","volume":"113","author":"Fillmore","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.clgc.2022.11.020_bib0016","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.clgc.2022.11.020_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202755","article-title":"A method for achieving high response rates in national surveys of U.S. primary care physicians","volume":"13","author":"Brtnikova","year":"2018","journal-title":"PLoS One"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:49Z","timestamp":1761565009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322002579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1558767322002579"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.11.020","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}